Skip to main content
Article thumbnail
Location of Repository

Mechanisms of Rapamycin Toxicity in Pancreatic Beta Cells

By Adam Barlow

Abstract

Islet transplantation offers a potential cure for type I diabetes mellitus. The publication of the landmark Edmonton study in 2000, which reported insulin independence in seven consecutive patients, prompted increased interest in this therapy. However, enthusiasm was tempered when the 5 year follow up results of this study were published, with only 10% of recipients maintaining insulin independence. The cause for this graft loss is multifactorial, but there is in vivo and in vitro evidence that suggests immunosuppressive drug toxicity plays an important role. The aim of this thesis was to establish the effects of rapamycin, one of the primary immunosuppressants used in islet transplantation, on murine β cells and islets and elucidate the mechanisms of any toxicity seen. \ud The intracellular target for rapamycin is mTOR which exists in two complexes, mTORC1 and mTORC2. mTORC1 primarily regulates cell size and proliferation; whereas mTORC2 plays a key role in regulating cell survival via protein kinase B (PKB). \ud This thesis has demonstrated that rapamycin treatment results in significant reductions in glucose stimulated insulin secretion in the MIN6 mouse insulinoma cell line and isolated rat islets, as well as increased apoptosis in these cell types. Furthermore, it has shown that prolonged rapamycin results in inhibition of mTORC2 assembly, with resultant inhibition of PKB phosphorylation and activity. Overcoming rapamycin induced mTORC2 inhibition with an adenovirus encoding constitutively active PKB ameliorates the detrimental effects of rapamycin on both MIN6 cells and rat islets. This suggests that rapamycin toxicity is mediated predominantly via mTORC2 rather than mTORC1 inhibition. \ud This work brings into question the use of rapamycin as an immunosuppressant in islet transplantation and also highlights the key role of PKB in β cell survival. Therapies resulting in PKB activation may have the potential to improve outcomes of islet transplantation

Publisher: University of Leicester
Year: 2011
OAI identifier: oai:lra.le.ac.uk:2381/9467

Suggested articles

Citations

  1. 1894. Notes on diabetes treated with extract and by grafts of sheep's pancreas.
  2. (2004). A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin.
  3. (2001). A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.
  4. (1991). A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region.
  5. (1995). A selective decrease in the beta cell mass of human islets transplanted into diabetic nude mice.
  6. (2006). A significant role for histocompatibility in human islet transplantation.
  7. (2006). Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass.
  8. (2004). Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity.
  9. (2002). Activation of phosphatidylinositol 3-kinase contributes to insulin-like growth factor I-mediated inhibition of pancreatic beta-cell death.
  10. (2004). Adenoviral gene transfer of erythropoietin confers cytoprotection to isolated pancreatic islets.
  11. (2000). AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1.
  12. (1998). Akt activation by growth factors is a multiple-step process: the role of the PH domain.
  13. (1997). Akt phosphorylation of BAD couples survival signals to the cellintrinsic death machinery.
  14. (2002). Akt regulates growth by directly phosphorylating
  15. (2001). AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells.
  16. (1992). AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.
  17. (1996). Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA.
  18. (2008). Antiproinflammatory effects of sirolimus on human islet preparations.
  19. (2010). Augmentation of insulin secretion by leucine supplementation in malnourished rats: possible involvement of the phosphatidylinositol 3-phosphate kinase/mammalian target protein of rapamycin pathway. Metabolism: clinical and experimental,
  20. (1999). Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients.
  21. (2001). Autoantibody response to islet transplantation in type 1 diabetes.
  22. (2006). Autocrine insulin action activates Akt and increases survival of isolated human islets.
  23. (1988). Automated method for isolation of human pancreatic islets.
  24. (1995). Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death.
  25. (2002). Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia.
  26. (2008). Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice. Molecular and cellular biology,
  27. (2003). cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2.
  28. (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha.
  29. (2006). Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes?
  30. (2004). controls the actin cytoskeleton and is rapamycin insensitive.
  31. (1982). Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action.
  32. (2009). Critical roles for the TSC-mTOR pathway in {beta}-cell function. American journal of physiology.Endocrinology and metabolism,
  33. (2002). Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis.
  34. (2004). Cross-talk between phosphatidylinositol 3-kinase/AKT and c-jun NH2-terminal kinase mediates survival of isolated human islets.
  35. (1992). Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction.
  36. (1992). Cyclosporin A, the cyclophilin class of peptidylprolyl isomerases, and blockade of T cell signal transduction.
  37. (2008). Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Human molecular genetics,
  38. (2001). Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neuoverexpressing cells.
  39. (2004). Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet beta cells.
  40. (2009). DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.
  41. (2006). Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4.
  42. (2009). Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets.
  43. (1986). Direct effects of cyclosporin A on human pancreatic beta-cells.
  44. (2008). Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-dependent manner.
  45. (1999). Dissociation of the eukaryotic initiation factor4E/4E-BP1 complex involves phosphorylation of 4E-BP1 by an mTOR-associated kinase.
  46. (2005). Donor islet endothelial cells participate in formation of functional vessels within pancreatic islet grafts.
  47. (2009). Effect of glucagon-like peptide-1 on beta- and alpha-cell function in isolated islet and whole pancreas transplant recipients.
  48. (2005). Effect of the immunosuppressive regime of Edmonton protocol on the long-term in vitro insulin secretion from islets of two different species and age categories. Toxicology in vitro : an international journal published in association with
  49. (2003). Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity?
  50. (2003). Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochemical and biophysical research communications,
  51. (2008). Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation.
  52. (2000). Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway.
  53. (1990). Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms.
  54. (2001). Eukaryotic initiation factor 2B: identification of multiple phosphorylation sites in the epsilon-subunit and their functions in vivo. The EMBO journal,
  55. Evidence that rapamycin inhibits interleukin-12-induced proliferation of activated T lymphocytes.
  56. (2009). Exenatide use in islet transplantation: words of caution.
  57. (2010). Exendin-4 protects pancreatic beta cells from the cytotoxic effect of rapamycin by inhibiting JNK and p38 phosphorylation. Hormone and metabolic research
  58. (2005). Five-year follow-up after clinical islet transplantation.
  59. (1991). FK 506-binding protein proline rotamase is a target for the immunosuppressive agent
  60. (2002). FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer.
  61. (2003). FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons.
  62. (2003). GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR.
  63. (2009). Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop.
  64. (2004). Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells.
  65. (2002). Glucose promotes pancreatic islet beta-cell survival through a PI 3-kinase/Akt-signaling pathway.
  66. (1999). Glutamic acid decarboxylase antibodies are more frequent than islet cell antibodies in islet transplanted IDDM patients and persist or occur despite immunosuppression.
  67. (2009). Glycogen synthase kinase-3 and mammalian target of rapamycin pathways contribute to DNA synthesis, cell cycle progression, and proliferation in human islets.
  68. (2002). Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation.
  69. (2002). Graft vascular function after transplantation of pancreatic islets.
  70. (2008). Has time come for new goals in human islet transplantation? American journal of transplantation :
  71. (2001). Hierarchical phosphorylation of the translation inhibitor 4E-BP1.
  72. (2009). Histologic graft assessment after clinical islet transplantation.
  73. (1994). Human pancreatic islet isolation and transplantation.
  74. (2003). Human, nonhuman primate, and rat pancreatic islets express erythropoietin receptors.
  75. (2008). Hyperglycemia induces apoptosis of human pancreatic islet endothelial cells: effects of pravastatin on the Akt survival pathway.
  76. (2000). Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice.
  77. (1995). Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.
  78. (2007). Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif.
  79. (2003). Identification of a proline-rich Akt substrate as a 14-3-3 binding partner.
  80. (1995). Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycinassociated protein and characterization of a critical serine residue.
  81. (2007). Identification of Protor as a novel Rictor-binding component of mTOR complex-2.
  82. (2006). Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity.
  83. (2006). Imaging islets labeled with magnetic nanoparticles at 1.5
  84. (1997). Improved human islet isolation using a new enzyme blend,
  85. (1960). Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes mellitus. Archives of surgery
  86. (2007). In vivo and in vitro effect of sirolimus on insulin secretion.
  87. (1998). In vivo evidence that erythropoietin protects neurons from ischemic damage.
  88. (1993). Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growthfactor signalling.
  89. (2004). Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies.
  90. (1999). Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation?
  91. (1997). Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways.
  92. (2000). Influence of sex and age at onset on autoantibodies against insulin, GAD65 and IA2 in recent onset type 1 diabetic patients.
  93. (2009). Influence of sirolimus on cyclosporine-induced pancreas islet dysfunction in rats.
  94. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase
  95. (2003). Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice.
  96. (1977). Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Canadian journal of physiology and pharmacology,
  97. (2002). Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets.
  98. (2000). Insights from a successful case of intrahepatic islet transplantation into a type 1 diabetic patient.
  99. (2003). Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.
  100. (2003). Insulin independence following isolated islet transplantation and single islet infusions.
  101. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase
  102. (2007). Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40.
  103. (1992). Insulin-dependent formation of a complex containing an 85-kDa subunit of phosphatidylinositol 3-kinase and tyrosinephosphorylated insulin receptor substrate 1.
  104. (1997). Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.
  105. (2006). International trial of the Edmonton protocol for islet transplantation. The New England journal of medicine,
  106. (1992). IRS-1 activates phosphatidylinositol 3'-kinase by associating with src homology 2 domains of p85.
  107. (2001). Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia.
  108. (1992). Islet cell allotransplantation in diabetic patients. Histologic findings in four adults simultaneously receiving kidney or liver transplants.
  109. (2008). Islet transplantation for brittle type 1 diabetes: the UIC protocol.
  110. (2000). Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. The New England journal of medicine,
  111. (2008). Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes.
  112. (2000). Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Upsala journal of medical sciences,
  113. (2009). Low revascularization of human islets when experimentally transplanted into the liver.
  114. (2007). Magnetic resonance imaging of gadolinium-labeled pancreatic islets for experimental transplantation.
  115. (2005). Magnetic resonance imaging of intrahepatically transplanted islets using paramagnetic beads.
  116. (1995). Maximal activation of transcription by
  117. (1995). Mechanism of action of mycophenolate mofetil.
  118. (1996). Mechanism of activation of protein kinase B by insulin and IGF-1.
  119. (1967). Method for the isolation of intact islets of Langerhans from the rat pancreas.
  120. (2001). Mitochondrial function in normal and diabetic beta-cells.
  121. (1991). Molecular cloning and characterisation of a
  122. (1991). Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily.
  123. (1991). Molecular cloning of a second form of rac protein kinase.
  124. (2008). mTOR complex 2 (mTORC2)
  125. (2007). mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex.
  126. (2008). mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes.
  127. (2006). mTOR inhibition induces endothelial progenitor cell death.
  128. (2002). mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.
  129. (2009). mTORC1 activation regulates beta-cell mass and proliferation by modulation of cyclin D2 synthesis and stability.
  130. (1998). Mutation analysis of the PTEN/MMAC1 gene in lung cancer.
  131. (2005). Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible blood.
  132. (2009). New insights into mTOR signaling: mTORC2 and beyond.
  133. (2008). Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus.
  134. Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability.
  135. (2005). Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of
  136. (1993). Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets.
  137. (1990). Pancreatic islet transplantation after upper abdominal exenteration and liver replacement.
  138. (2008). Pathology of an islet transplant 2 years after transplantation: evidence for a nonimmunological loss.
  139. (2003). Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects.
  140. (2005). PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.
  141. (2001). Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K.
  142. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases.
  143. (1990). Phosphorylation of the PDGF receptor beta subunit creates a tight binding site for phosphatidylinositol 3 kinase.
  144. (1999). Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B.
  145. (2002). PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.
  146. (2002). PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest.
  147. (2004). Portal vein thrombosis complicating islet transplantation in a recipient with the Factor V Leiden mutation.
  148. (2005). Positron-emission tomography imaging of early events after transplantation of islets of Langerhans.
  149. (2005). Prevention of bleeding after islet transplantation: lessons learned from a multivariate analysis of 132 cases at a single institution. American journal of transplantation :
  150. (2002). Prevention of primary nonfunction of canine islet autografts by treatment with pravastatin.
  151. (1990). Probing immunosuppressant action with a nonnatural immunophilin ligand.
  152. (2002). Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation.
  153. (1997). Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts.
  154. (2008). Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. American journal of transplantation :
  155. (2007). Protective effect of erythropoietin against ketamine-induced apoptosis in cultured rat cortical neurons: involvement of PI3K/Akt and GSK-3 beta pathway. Apoptosis :
  156. (2002). Protein kinase B/Akt prevents fatty acid-induced apoptosis in pancreatic beta-cells (INS-1).
  157. (2002). Protein kinase C alpha (PKC alpha): regulation and biological function.
  158. (2002). Protein phosphatase 2A is the main phosphatase involved in the regulation of protein kinase B in rat adipocytes.
  159. (1991). Quantitative and qualitative standards for islet isolation assessment in humans and large mammals.
  160. (2006). Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival.
  161. (1994). RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.
  162. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets.
  163. Rapamycin impairs in vivo proliferation of islet beta-cells.
  164. (2010). Rapamycin impairs metabolism-secretion coupling in rat pancreatic islets by suppressing carbohydrate metabolism. The Journal of endocrinology,
  165. (2007). Rapamycin regulates the phosphorylation of rictor.
  166. (1991). Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein. Molecular and cellular biology,
  167. (1997). Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k.
  168. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
  169. regulation of Akt/PKB by the rictor-mTOR complex.
  170. (2001). Regulation of pancreatic betacell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha.
  171. (2003). Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. The Biochemical journal, 370(Pt 2),
  172. (2008). Regulation of TORC1 by Rag GTPases in nutrient response.
  173. (2009). Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation. Clinical and experimental immunology,
  174. (2003). Rheb GTPase is a direct target of
  175. (2003). Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.
  176. (2003). Rheb is an essential regulator of S6K in controlling cell growth in Drosophila.
  177. (2003). Rheb promotes cell growth as a component of the insulin/TOR signalling network.
  178. (2005). Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis.
  179. (2010). Rictor is a novel target of
  180. (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.
  181. (2004). S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Molecular and cellular biology,
  182. (2009). Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling.
  183. (2002). Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells.
  184. (2000). Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR.
  185. (2005). Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion.
  186. (2000). Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI.
  187. (2006). Signalling through Class I PI3Ks in mammalian cells.
  188. (2002). Simvastatin induces activation of the serine-threonine protein kinase AKT and increases survival of isolated human pancreatic islets.
  189. (2006). SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity.
  190. (2006). Sirolimus is associated with reduced islet engraftment and impaired beta-cell function.
  191. (2004). Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase.
  192. (1996). Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP.
  193. (2003). Successful human islet isolation utilizing recombinant collagenase.
  194. (1996). Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes.
  195. (2008). Syndecan-4 regulates subcellular localization of mTOR Complex2 and Akt activation in a PKCalpha-dependent manner in endothelial cells.
  196. (2010). Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy.
  197. (1991). Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast.
  198. (2005). Technique, complications, and therapeutic efficacy of percutaneous transplantation of human pancreatic islet cells in type 1 diabetes: the role of US.
  199. (2003). The bag method for islet cell infusion.
  200. (1994). The correlation between donor characteristics and the success of human islet isolation.
  201. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. The New England journal of medicine,
  202. (2002). The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor.
  203. (2002). The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth.
  204. (2007). The hallmark of AGC kinase functional divergence is its C-terminal tail, a cis-acting regulatory module.
  205. (2006). The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity.
  206. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.
  207. (1996). The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients.
  208. (1995). The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase.
  209. (2008). The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science
  210. (2009). The RhoGDI-alpha/JNK signaling pathway plays a significant role in mycophenolic acid-induced apoptosis in an insulin-secreting cell line.
  211. (2009). The TSC-mTOR pathway mediates translational activation of TOP mRNAs by insulin largely in a raptor- or rictor-independent manner. Molecular and cellular biology,
  212. (2008). The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects.
  213. (1991). Toxicity of rapamycin--a comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat.
  214. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell.
  215. (2004). Transplantation for type I diabetes: comparison of vascularized whole-organ pancreas with isolated pancreatic islets.
  216. (1998). Transplantation of allogeneic islets of Langerhans in the rat liver: effects of macrophage depletion on graft survival and microenvironment activation.
  217. (2002). Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling.
  218. (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.
  219. (2003). TSC2 mediates cellular energy response to control cell growth and survival.
  220. (2002). Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
  221. (1988). Type I phosphatidylinositol kinase makes a novel inositol phospholipid,
  222. (1999). Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines.
  223. (2004). Upstream and downstream of mTOR.
  224. (2007). Vascular endothelial growth factor as a survival factor for human islets: effect of immunosuppressive drugs.
  225. (2008). Widespread amyloid deposition in transplanted human pancreatic islets. The New England journal of medicine,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.